Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy
RR Wexler, WJ Greenlee, JD Irvin… - Journal of Medicinal …, 1996 - ACS Publications
The renin-angiotensin system (RAS) is recognized as a key element in blood pressure
regulation and electrolyte/fluid homeostasis. 1 As outlined in Figure 1, the RAS constitutes a …
regulation and electrolyte/fluid homeostasis. 1 As outlined in Figure 1, the RAS constitutes a …
Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?
EMV de Cavanagh, F Inserra… - Cardiovascular research, 2011 - academic.oup.com
Protein and lipid oxidation—mainly by mitochondrial reactive oxygen species (mtROS)—
was proposed as a crucial determinant of health and lifespan. Angiotensin II (Ang II) …
was proposed as a crucial determinant of health and lifespan. Angiotensin II (Ang II) …
Атеросклероз: патогенез, клиника, функциональная диагностика, лечение
РС Карпов, ВА Дудко - 1998 - elibrary.ru
В книге рассмотрены современные патогенные, патофизиологические, клинические,
инструментальные и терапевтические аспекты атеросклеротического повреждения …
инструментальные и терапевтические аспекты атеросклеротического повреждения …
Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers
Background—Little is known about the pathophysiology of myxomatous degeneration of the
mitral valve, the pathological hallmark of mitral valve prolapse, associated with symptomatic …
mitral valve, the pathological hallmark of mitral valve prolapse, associated with symptomatic …
The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
OVEK ANDERSSON, S NELDAM - Blood Pressure, 1998 - Taylor & Francis
This multicentre study compared the antihypertensive effect and tolerability of the novel
angiotensin II antagonist candesartan cilexetil with those of losartan and placebo. Men and …
angiotensin II antagonist candesartan cilexetil with those of losartan and placebo. Men and …
Sacubitril/valsartan (LCZ696) in heart failure
Y Khder, V Shi, JJV McMurray, MP Lefkowitz - Heart Failure, 2017 - Springer
It has been known since the 1990s that long-term morbidity and mortality is improved in
patients with heart failure with reduced ejection fraction (HFrEF) by treatments that target the …
patients with heart failure with reduced ejection fraction (HFrEF) by treatments that target the …
Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with …
JR Benz, HR Black, A Graff, A Reed… - Journal of human …, 1998 - nature.com
Objective: This study compares the antihypertensive efficacy and tolerability of valsartan, a
novel angiotensin II antagonist, given with hydrochlorothiazide (HCTZ) vs placebo or vs …
novel angiotensin II antagonist, given with hydrochlorothiazide (HCTZ) vs placebo or vs …
A story of two ACEs
U Danilczyk, U Eriksson, MA Crackower… - Journal of molecular …, 2003 - Springer
Abstract According to the World Health Organization predictions cardiovascular diseases
will be the leading cause of death by the year 2020. High blood pressure is a major risk …
will be the leading cause of death by the year 2020. High blood pressure is a major risk …
Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
R Hübner, AM Högemann, M Sunzel… - Journal of human …, 1997 - search.ebscohost.com
Candesartan cilexetil is rapidly and completely hydrolysed to the active compound
candesartan during absorption from the gastrointestinal tract. Candesartan is a potent, long …
candesartan during absorption from the gastrointestinal tract. Candesartan is a potent, long …
Pathogenic role of the renin–angiotensin system in modulating radiation-induced late effects
ME Robbins, DI Diz - International Journal of Radiation Oncology* Biology …, 2006 - Elsevier
With ongoing improvements in cancer therapy and health care, the population of long-term
cancer survivors continues to grow: 62% of adult and 77% of pediatric cancer patients …
cancer survivors continues to grow: 62% of adult and 77% of pediatric cancer patients …